Search
Protagonist Therapeutics Inc
PTGXAdd to Watchlist
132.040USD
-3.220-2.38%
Close 11-06 16:00（ET）
8.54BMarket Cap
LossP/E TTM
Protagonist Therapeutics Inc (PTGX) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Protagonist Therapeutics Inc in the past month.
Buy
5 Strong Buy
9 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
179.429USD+23.87%
PTGX Analyst Recommendation Trends
In the current month, PTGX has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the last month is 179.429.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
5
4
4
4
9
9
8
8
8
8
8
8
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
14
14
14
13
13
13
PTGX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, PTGX EPS is projected to reach -0.422 in FY2026Q4, following reported EPS of 3.315 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.53
2.08
2.44
-0.42
-0.24
Actual
0.06
2.47
3.32
--
--
Surprise
+110.91%
+18.62%
+35.76%
--
--
FAQs
What is Protagonist Therapeutics Inc's expected revenue for the next quarter?
Protagonist Therapeutics Inc's expected revenue is 37.73M.
What is Protagonist Therapeutics Inc's price target?
Analysts forecast that Protagonist Therapeutics Inc's price target is USD 179.43, with the highest forecast at USD 225.00 and the lowest forecast at USD 160.00.
How have Protagonist Therapeutics IncPTGX's recent earnings per share performed?
The market expectation was USD 3.32, while Protagonist Therapeutics IncPTGX's earnings per share (EPS) for the previous quarter was USD 2.47. EPS for the next quarter is expected at USD -0.42.
What is the analyst rating for Protagonist Therapeutics Inc?
Based on the ratings of Protagonist Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.